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Abstract
Systemic arterial hypertension is an important risk factor for cardiovascular disease that is frequently observed in
populations with declining renal function. Initiation of renal replacement therapy at least partially decreases signs of fluid
overload; however, high blood pressure levels persist in the majority of patients after dialysis initiation. Hypervolemia due to
water retention predisposes peritoneal dialysis (PD) patients to hypertension and can clinically manifest in several forms,
including peripheral edema. The approaches to detect edema, which include methods such as bioimpedance, inferior vena
cava diameter and biomarkers, are not always available to physicians worldwide. For clinical examinations, the presence of
pitting located in the lower extremities and/or over the sacrum to diagnose the presence of peripheral edema in their
patients are frequently utulized. We evaluated the impact of edema on the control of blood pressure of incident PD patients
during the first year of dialysis treatment. Patients were recruited from 114 Brazilian dialysis centers that were participating
in the BRAZPD study for a total of 1089 incident patients. Peripheral edema was diagnosed by the presence of pitting after
finger pressure was applied to the edematous area. Patients were divided into 2 groups: those with and without edema
according to the monthly medical evaluation. Blood arterial pressure, body mass index, the number of antihypertensive
drugs and comorbidities were analyzed. We observed an initial BP reduction in the first five months and a stabilization of
blood pressure levels from five to twelve months. The edematous group exhibited higher blood pressure levels than the
group without edema during the follow-up. The results strongly indicate that the presence of a simple and easily detectable
clinical sign of peripheral edema is a very relevant tool that could be used to re-evaluate not only the patient’s clinical
hypertensive status but also the PD prescription and patient compliance.
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Introduction
Cardiovascular disease is the most common cause of morbidity
and mortality in patients with chronic kidney disease (CKD) [1–3].
Systemic arterial hypertension (SAH) is an important risk factor
for cardiovascular disease and is frequently observed in this
population along with a decline of renal function [4]. Although
overload and renal replacement therapy (RRT) with dialysis
usually improve fluid balance and partially remove uremic toxins,
high blood pressure levels may persist after the initiation of
dialysis, and hypertension is present in the majority of both
peritoneal and hemodialysis patients [5,6].
The reduction in blood pressure levels observed in peritoneal
dialysis (PD) patients can be attributed to the continuous effective
control of fluid balance and, consequently, extracellular volume
[7]; however, this reduction is not always sustained. In fact, higher
than normal blood pressure levels are observed in many patients
during dialysis therapy, mainly due to the limitations in achieving
normal fluid status [8–10]. Hypervolemia due to water retention
predisposes PD patients to hypertension [11,12] and can manifest
clinically in several forms, including peripheral edema [9].
Detecting occult edema often involves the measurement of metrics
such as bioimpedance, inferior vena cava diameter and biomark-
ers, but these methods are not available to all physicians. To detect
edema in their patients, many doctors have at their disposal only
the presence of pitting located in the lower extremities and/or over
the sacrum.
Despite the fact that some patients present SAH independently
of volemic status, it is recognized that hypervolemia, with or
without the presence of edema, is one of the principal factors
responsible for the resistance of PD patients to SAH treatment
[13,14]. Blood pressure normalization often requires modifications
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decrease in fluid and sodium intake, blood sugar control and/or
an increase in the number of prescribed hypertension drugs
[6,7,15,21]. Considering that the expansion of extracellular
volume can occur during dialysis and that peripheral edema
detectable on a physical exam can be the result of a hypervolemic
state [13], little is known about the correlations between pitting
edema and blood pressure control in hypertensive patients
receiving PD treatment.
We hypothesized that the presence of pitting edema is
associated with the worsening of SAH, which leads to the
cardiovascular impact observed in fluid-overloaded patients. Thus,
in the present study, we evaluated the impact of peripheral edema
on hypertensive control in incident PD patients with SAH during
the first year of dialysis treatment.
Methods
Each consecutive incident patient recruited from 114 Brazilian
dialysis centers participating in the BRAZPD study from
December 2004 through October 2007 was included, totaling
3439 patients. Incident patients were defined as patients who
originated from pre-dialysis conservative treatment or HD, who
started treatment with PD during the study period and who
remained on the therapy for at least 90 days. In Brazil, 60% of the
patients start treatment in APD and 40% in CAPD. Details of the
BRAZPD study design and characteristics of the cohort are
described elsewhere [16]. Briefly, after being selected to participate
in the study, each clinic submitted the project to its local ethics
committee (the protocol was approved by the ethics committees of
Federal University of Uberlandia), and all patients signed an
informed consent. Physician and nurses at each dialysis center
were trained by the study monitors to use the clinical research
software PDnet, which was designed specifically to collect data for
this study. From a total of 3439 incident patients, 239 were
excluded because they were less than 18 years old, 1650 were
excluded for not completing 12 full months of follow up (i.e.,
patients who missed at least one medical evaluation monthly for 12
consecutive months, or who dropped out due to hemodialysis,
transplant or death), 430 were excluded because they were
normotensive with or without previously using any antihyperten-
sive drugs and because they did not have peripheral edema at the
beginning of the PD treatment, and 31 were excluded due to
missing data. After exclusion criteria were applied, 1089 hyper-
tensive patients were included in the analysis.
The variables analyzed included anthropomorphic data,
comorbidities, systolic arterial pressure (SAP), diastolic arterial
pressure (DAP), mean arterial pressure (MAP), erythropoietin use,
PD modality (CAPD or APD), and physical examination. During
the physical examination, peripheral edema was characterized by
the presence of pitting after finger pressure was applied to the
edematous area for at least five seconds. The nephrologists graded
pitting edema on a scale from 1+ to 4+. The urea and plasma
creatinine, serum potassium, and hemoglobin values of the
patients were measured to be used as annual means.
For all patients, the dialysis nurse or the nephrologist measured
blood pressure during their monthly visits to the dialysis clinic. For
the diagnosis of systemic hypertension, the following WHO/ISH
criteria were applied: SAP$140 mmHg and/or DAP$90 mmHg,
with or without the use of hypertensive medication. SAP levels
were verified using an oscillating method. Mean arterial pressure
was calculated using the formula MAP=(2DAP+SAP)/3. The
number of anti-hypertensive drug classes used monthly by the
patients (NAC) was also reported. The classes considered were
diuretics, beta-blockers, ACE inhibitors, angiotensin II receptor
blockers, centrally and peripherally acting alpha-blockers, and
calcium channel blockers. Each class listed was counted as one
unit, and the NAC represented the mathematical mean of the
number of anti-hypertensive drug classes used per patient for each
subgroup.
After the exclusion criteria were applied, the final sample
consisted of 1089 hypertensive patients. These patients were
subdivided into those with (E+) and without (E2) clinically
detectable pitting edema, according to the monthly medical
evaluation at both the beginning of the observation period and
during the twelve months of follow up. The number of patients in
each subgroup varied monthly depending on the presentation of
edema at that particular evaluation (Figure 1). In order to analyze
the trend for edema and high blood pressure levels, we also
monitored for 12 months the patients classified E+ and E2 based
on the first month classification.
Statistical Analysis
Categorical variables are presented as frequencies and percent-
ages. Continuous variables are presented as the mean 6 standard
deviation (mean 6 SD). In the figures, continuous variables are
presented as the mean 6 standard error. The chi-squared test and
analysis of variance (ANOVA), with repeat measures and
measures of position and distribution, were utilized for the
comparison between the E+ and E2 subgroups. The parallelism
analysis of both groups was performed to verify the trends and
similarities between the groups, for the initial defined groups at
month 1. For all analyses, a p-value of ,0.05 was considered
statistically significant. All statistical analyses were performed using
SPSS version 8.0 (Chicago, IL, USA).
Results
Descriptive data at baseline PD treatment level (after the first
month on PD) for all patients included in this study are shown in
Table 1. The mean patient age was 58.2615.3 years, and more
than half (56.9%) of the patients were female. The mean SBP was
156.7618.7 mmHg, the mean DBP was 90.0612.7 mmHg, and
the mean MAP was 112.2612.8 mmHg. The mean body mass
index (BMI) was 25.465.0 kg/m
2. The correlation between BMI
and the number of patients with edema was negative and
significant (r=20.83). The increase of blood pressure (SBP,
DBP and MAP) correlated with the number of patients with
Figure 1. Number of patients/month with clinically detectible
edema.
doi:10.1371/journal.pone.0036758.g001
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of study participants were diabetic, and the mean number of anti-
hypertensive class drugs (NAC) used was 2.161.0 drugs/patient.
Forty-three percent of patients were on APD using Home-
choice
TM (Baxter Healthcare) as the cycler, and all patients were
prescribed only glucose-based PD solutions (Dianeal, Baxter
Healthcare).
Analysis of groups divided by the presence of clinically
detectible edema
Subgroup analysis of patients with clinically detectible
edema (E+)
During the study, subgroup E+ (n=307) presented a decrease in
SAP between the 1
st and 5
th month (from 159.5619.6 to
150.0625.3 mmHg, p,0.05), and SAP remained constant from
the 5th month until the end of the study (151.2630.3 mmHg,
p.0.05). DAP did not change significantly between the 1
st and
12
th month (from 90.7613.3 to 89.0617.7 mmHg, p.0.05). SAP
decreased significantly between the 1st and 5th month (from
113.7613.4 to 108.0617.2 mmHg, p,0.05), and MAP remained
constant from the 5
th month through the 12
th month
(109.7619.8 mmHg, p.0.05). NAC did not change between the
1st and 12th months (from 2.361.0 to 2.261.0 drugs/patient,
p.0.05). The number of patients with edema decreased between
the 2nd and 6th months from 307 to 245 individuals; this number
varied through the end of the evaluation period, at which point
243 patients were clinically diagnosed with edema (Figure 1). BMI
Table 1. Demographic, clinical and laboratory characteristics of patients at the baseline evaluation.
Variable Total Patients
population with edema (E+) without edema (E2) P value
Number of patients (n) 1089 307 782 ,0.001
Age (year) 58.2615.3 59. 6614.3 57.7615.6* 0.03
Female (%) 56.9 55.7 57.4 0.61
Diabetes (%) 42.6 56.0 37.3* ,0.0001
Race (%)
Asian 2.7 3.2 2.8 0.92
White 61.7 61.6 61.1 0.96
Black 35.6 35.2 36.1 0.93
Height (cm) 161.6610.0 161.6610.5 161.769.8 0.44
Weight (Kg) 66.7615.0 69.8614.5 65.5615.1* ,0.0001
Body mass index (Kg/m2) 25.465.0 26.765.1 24.964.9* ,0.0001
SAP (mmHg) 156.7618.7 159.5619.6 155.6618.2* 0.001
DAP (mmHg) 90.0612.7 90.7613.3 89.7612.5 0.11
MAP (mmHg) 112.2612.8 113.7613.4 111.7612.6* 0.01
NCA 2.161.0 2.361.0 2.060.7* ,0.0001
Erythropoietin (%) 44.0 51.0 41.2* 0.003
CAPD/APD (%) 57.0/43.0 63.5/36.5 55.5*/44.5* 0.01/0.02
Conservative treatment (%) 56.2 60.4 54.7 0.093
Serum Albumin (g/dL)(n) 3.660.69 3.5460.78 3.6460.64 0.295
Hemodialysis previously (%) 44.5 44.4 44.6 0.933
Serum urea (mg/dl) 101.2624.8 124.5626.2 101.8624.9 0.34
Serum creatinine (mg/dl) 8.063.1 7.863.1 8.163.1 0.12
Serum potassium (mEq/L) 4.360.6 4.360.6 4.460.6 0.08
Haemoglobin (g/dl) 11.564.0 11.463.7 11.564.1 0.44
NCA, number of classes of anti-hypertensives in use;
*(E2) vs (E+);
SAP: systolic arterial pressure; DAP: diastolic arterial pressure;
MAP: mean arterial pressure.
doi:10.1371/journal.pone.0036758.t001
Figure 2. Twelve-month evolution of the body mass index
(BMI) in the patient cohort.
doi:10.1371/journal.pone.0036758.g002
Edema and Hypertension in Peritoneal Dialysis
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36758increased from the 2
nd to the 12
th month of evaluation (from
26.765.1 to 28.165.6 kg/m2, p,0.05) (Figure 2).
Subgroup analysis of patients without clinically
detectible edema (E2)
Subgroup E2 (n=782) presented a significant decrease in SAP
between the 1st and 5th month (from 155.6618.2 to
142.7624.2 mmHg, p,0.05). After this initial period, SAP
remained constant until the end of the study period
(141.2626.6 mmHg, p.0.05). DAP did not change between the
1st and 12th months (89.7612.5 to 84.7615.8 mmHg, p.0.05).
MAP decreased significantly between the 1st and 5th months
(from 111.7612.6 to 104.1615.8 mmHg, p,0.05) and then
remained constant from the 5
th month through the 12
th month
(103.6617.9 mmHg, P.0.05). NAC did not vary throughout the
study period; the mean at the 1st month was 2.060.7, and the
mean at the 12th month was 2.161.1 (p.0.05). For subgroup E2,
there was no difference in BMI during the 12 months of follow-up
(Figures 3 and 4)).
Comparison between the two subgroups of patients
The descriptive characteristics of the two subgroups defined by
the presence of edema at the start of dialysis are shown in Table 1.
At baseline, subgroup E+ consisted of 307 patients and E2
consisted of 782 patients; however, these numbers varied
according to monthly clinical evaluations (Figure 1). When only
the patients classified E+ and E2 in the first month were
monitored, the results confirmed the monthly patient classification.
E+ and E2 move in the same way for the SBP (p=0.654)
although with different mean profiles (p=0.001). In other words,
E+ group showed higher SAP values than E-group during the 12
months period. For the DAP and MAP the trend and mean profile
did not show statistical diferences (Figure 4). A comparison of
subgroups E+ and E2 at the start of treatment (Table 1) revealed
significant differences with respect to age (59.6614.3 vs.
57.7615.6 years, respectively; p,0.03), BMI (26.765.1 vs.
24.964.9 kg/m2, respectively; p,0.0001), SAP (159.5619.6 vs.
155.6618.2 mmHg, respectively; P,0.001), MAP (113.7613.4
vs. 111.7612.6 mmHg, respectively; P,0.01), NAC (2.361.0 vs.
2.060.7 drugs/patient, respectively; P,0.05) and erythropoietin
use (51.0 vs. 41.2%, respectively; P=0.003). In both subgroups,
there were a greater percentage of patients on APD than on
CAPD (63.5/36.5 vs. 55.5/44.5%, respectively; p,0.01/0.02).
The percentage of patients with diabetes mellitus was greater in
subgroup E+ than in subgroup E2 (56.0 vs. 37.3%, respectively;
P,0.0001), and the number of patients with a history of
cardiovascular disease at the start of PD was not significantly
different between the two groups (Table 1). SAP, MAP, NAC, and
BMI were significantly different between the two subgroups (E+
and E2) in the analysis of the entire follow up period (p,0.05).
Discussion
It is well known that the expansion of extracellular volume with
or without detectible edema is one of the principal factors
responsible for the increase in SAP in patients with CKD [3,9]. In
the present study, we observed that SAP and MAP of both
subgroups presented a significant decrease in values in the first five
months after starting PD therapy and stabilization of these values
through the end of the observation period. This behavior was also
conferred by Menon et al. [17], who reported a reduction in
systemic pressures at the start of PD and, contrary to our data,
detected an increase in blood pressure levels after 6–12 months on
PD. On the other hand, Saldanha et al. [7] reported a decrease in
blood pressure levels during PD treatment over 5 years, which was
associated with the concomitant increase in the number of anti-
hypertensive drugs used. In the present study, the initial decline
observed in the E+ and E2 groups could be attributed to a
reduction in extracellular volume as a result of PD [8,18] because
NAC did not change during this period. However, it should be
noted that NAC represents a number of anti-hypertensive classes
of drugs, which allows for the possibility of variations in the
measurement of anti-hypertensive drugs within the same class. On
the other hand, NAC maintenance can reflect a non-worsening of
SAH in these patients and/or the medical preference to use these
drugs for other therapeutic goals such as cardio-protection and/or
preservation of residual renal function. Despite the initial decline
in arterial blood pressure levels observed in our study, they did not
decrease to values within the normal limits; SAP levels were above
140 mmHg during the entire study period. There are other
reasons that could explain in the relative control of blood pressure
levels in both groups, which are increase activity of the
sympathetic nervous system, increase endothelium-derived vaso-
constrictors, vascular calcification and activation of the renin-
angiotensin system.
Upon separate analysis of the E+ and E2 groups, we observed a
monthly variation throughout the study period in the number of
patients. This variation was a consequence of bi-directional flow
between these groups. Despite this, the number of patients in the
E+ subgroup decreased significantly after 12 months, from 307 to
243 patients (Figure 1). Among the E+ subgroup, SAP and MAP
levels decreased from baseline until the 5th month, at which time
they stabilized until the 12
th month (Figure 3 and 4), while DAP
did not change significantly during the entire period. In our study,
patients with edema exhibited greater blood pressure levels (SAP
and MAP) than those observed in the E2 subgroup (Figure 3 and
4). Gunal et al. [12] and Katzarski et al. [19] demonstrated that
volume overload is an important factor in resistance to SAH
treatment for dialysis patients, while Ates et al. [20] showed that
SBP and DBP were negatively correlated with total fluid and
sodium removal, as well as with sodium restriction. The increase of
blood pressure values was correlated with the number of patients
with edema. This association shows that the patients who belonged
to the E+ had higher blood pressure levels than those of group E2
(Figure 5).
Our data demonstrated that the NAC in the E+ subgroup,
despite not varying throughout the study, was significantly greater
than in the E2 subgroup during the months evaluated. This
observation may suggest a greater difficulty in SAH control in the
Figure 3. Systolic (SBP), Diastolic (DBP) and Mean Arterial
Pressures (MAP) in incident PD patients during 12 months of
follow up.
doi:10.1371/journal.pone.0036758.g003
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progressively over the 12 month period. A strong and negative
correlation between BMI and the number of patients with edema
was observed. This association could be explained in two ways: a
worsening of the edema status during PD therapy or a real gain of
body mass. We believe that future studies with adequate designs
will help to answer this question.
The progressive increase in body weight, likely caused to a large
extent by the presence of edema, can be attributed to a water and
salt imbalance, the patient’s failure to follow medical recommen-
dations, and/or an inadequate PD prescription. The progressive
increase in body weight among PD patients might also be
attributed to a gain of fat mass due to glucose absorption from the
peritoneal cavity, as the patients may have been prescribed more
hypertonic PD solutions to improve UF.
In the E2 subgroup, blood pressure patterns followed the trend
observed in the E+ group and decreased in the first months of PD
before subsequently stabilizing (Figure 3). In the E2 group, blood
pressure levels were lower than those observed in the E+ group
during the entire observation period, whereas the NAC in the E2
group did not vary significantly during the study period. However,
blood pressure values did not reach the normal recommended
levels. In general, there are several associated factors that make
normalization of blood pressure levels difficult to attain in PD
patients, including the presence of diabetes mellitus, aging, and the
use of erythropoietin [11,14,18]. This was observed in the present
study in the E+ group, in which the patients were significantly
older and the percentage of patients with diabetes mellitus was
significantly greater than in the E2 group (Table 1). The
significantly larger number of E+ patients who were treated with
CAPD as opposed to APD may reflect an inadequate PD
prescription, as many of these CAPD patients may be high
transporters and/or have UF problems in the long run. Therefore,
these patients should have been switched to APD. However,
during the observation period, Extraneal was not available in
Brazil. Moreover, blood pressures above the normal values could
be caused by therapeutic inertia, where soft reasoning often leads
to avoidance of intensified therapy by the medical staff [21].
The present study presents several limitations. Edema evalua-
tion cannot be easily standardized, and the influence of expansion
or retraction of volume on the systemic pressure levels could be
better analyzed if it was evaluated by other methods, such as bio-
impedance, inferior vena cava diameter [22], and biomarkers such
as ANP [22,23]. This approach, however, is uncommon in daily
medical practice due to the need for tools that are not always
available. In addition, the analysis of fluid retention in PD patients
is limited by the absence of data regarding residual renal function,
the peritoneal membrane solute transport type and UF measure-
ments [9]. Hypoalbuminemia, and consequent water and sodium
retention, can explain the presence of edema and the difficulty in
normalizing pressure levels; however, an evaluation of the causes
of resistance to anti-hypertension therapy was not a focus of this
study. It is important to note that the results of this observational
study reflect PD practices in Brazil, which may be similar to
treatment practices in a large number of countries around the
world.
Figure 4. The initial groups (first month) were followed for 12 months.
doi:10.1371/journal.pone.0036758.g004
Figure 5. The increase in blood pressure levels correlates
positively to the number of patients with edema.
doi:10.1371/journal.pone.0036758.g005
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in blood pressure levels after the initiation of PD, which was more
pronounced in the first few months of therapy. However, most
patients do not achieve normalization during the first year of
treatment. This difficulty in reducing arterial blood pressure to
normal levels is aggravated by the presence of edema, which points
to a pivotal role of fluid overload in the hypertension of CKD
patients on dialysis. The presence of clinically detectible pitting
edema can be a useful clinical sign that could be used to guide the
optimization of SAH treatment in patients undergoing continuous
peritoneal dialysis.
In summary, volume status is of major importance to outcomes
in patients undergoing PD. The lack of a robust edema evaluation
and the limited availability of BIA and other objective measures of
quantifying volume status make clinicians highly dependent on
clinical evaluation. Clinically detectable pitting edema remains the
most readily used clinical assessment tool. This study is the first to
give a large-scale systematic description of pitting edema in the
context of arterial hypertension in PD patients and to assess the
effects of edema resolution in blood pressure values with PD
initiation.
The results presented here strongly indicate that the presence of
such a simple and easily detected clinical sign as pitting edema
should be considered to be a relevant observational tool to assess a
patient’s clinical status, PD prescription and compliance with
treatment. The term ‘‘back to basics’’ could mean, ‘‘examine your
patients, look for edema and observe the blood pressure’’ and to
do this sophisticated technologies are not needed.
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